

"PRESSORS"

↳ Activate Adrenergic Receptors to increase peripheral vasoconstriction

* GOAL: Increase tissue perfusion, especially in end organs who otherwise won't have enough perfusion to function adequately. *



Using pressors expects the following results:

- ↑ SVR (systemic vascular resistance)
- Normal Reference Range: 600 - 1200
- Measurement of AFTERLOAD

$$CO = IHR \times SV$$

(stroke volume)

Preload (temporary) ↓ Contractility ↑ Afterload (SVR)

Actions of Vasopressors

* α_1 Receptors - smooth muscle contraction

Alpha (α) Receptors

α_2 Receptors

* β_1 Receptors (Heart) - increase chronotropy and inotropy

Beta (β) Receptors

β_2 Receptors (Lungs) - smooth muscle relaxation in lungs

β_3 Receptors

V_1 Receptors - activated by vasopressin and causes smooth muscle contraction

ATII Receptors - activated by angiotensin II and causes peripheral vessel constriction

Agonist Drug: fully activates the receptor to which its bound

Antagonist Drug: does not activate the receptor and can block the effects of the other agonist

VASSOPRESSORS

Norepinephrine (Levophed)

- Usually FIRST-LINE pressor
- Primarily α agonist, has some β_1 agonist effects
 - causes relatively equal veno and arterial constriction
 - ↳ Extravasation could cause tissue necrosis and/or limb ischemia
- Dosing/concentration
 - Usually 4mg/250 mL (can come in 2, 8, or 16 mg as well)
 - Dose per literature = 1-12 mcg/min, but can vary in diff. hospitals
- Has rapid onset (~1 minute)
- can titrate every 3-5 minutes

Phenylephrine (Neosynephrine)

- Pure α receptor agonist which can cause a baroreceptor mediated bradycardia which could affect CO
- causes relatively equal veno and arterial constriction
 - ↳ Extravasation could cause tissue necrosis and/or limb ischemia
- Dosing/Concentration
 - Conc. usually 40mg/250 mL
 - Standard dose: 50-200 mcg/min
- Rapid onset (~1 minute)

• Can titrate every 3-5 minutes

Vasopressin

- Usually 2nd line in pts who are resistant to catecholamine pressors (i.e. Norepi)
- Impacts the Arginine-Vasopressin System (AVS) to ↑ BP
- Acts as a V₁ receptor site agonist
 - Also helps w/ water reabsorption in kidneys, thus helping ↑ BP
- Dosing/concentration
 - Conc. usually 20 Units/100 mL
 - Dose: 0.01-0.04 units/min (per pharm, 0.03 units/min)
- Onset is 5-15 min.
- **NON-TITRATABLE!**

Epinephrine

- Used when other meds have failed
- Nonselective Adrenergic Agonist (acts on α₁, α₂, β₁, β₂, and β₃)
- Larger doses select for α₁ and α₂ receptors
- Dosing/concentration
 - Conc. usually 1mg/250 mL
 - Dose: 1-10 mcg/min
- Onset usu 1-2 min
- Titrate every 5-10 min

Dopamine

- Dose dependent effects:
 - α or β agonist depending on dose
- Dosing/concentration
 - Conc. usu 400mg/250 mL
 - Dose: 2-20 mcg/kg/min
 - 0.5-2 (Renal dose)
 - 5-10 (Inotropic Effect; β agonist)
 - 10-20 (Adrenergic Effect; α agonist)
- Onset usually 5 minutes
- Titrate every 10 minutes

	α	β ₁	β ₂	SVR	HR	Inotropy
Norpinephrine (Levophed)	↑↑↑	↑	⊘	↑↑↑↑	↑↑	↑
Phenylephrine (Neosynephrine)	↑↑↑	⊘	⊘	↑↑↑↑	↓	⊘
Vasopressin V ₁	⊘	⊘	⊘	↑↑↑↑	⊘	⊘
Epinephrine	↑↑↑	↑↑	↑	↑↑↑↑	↑↑↑	↑↑↑
Dopamine	↑↑↑	↑↑↑	↑	↑↑↑	↑↑↑	↑↑
Angiotensin II (Niaapreza) ATII	⊘	⊘	⊘	↑↑	⊘	⊘

Angiotensin II (Niaapreza)

- Synthetic peptide of normal ATII found in our bodies
- New as of 2017
- Activates RAS system; specifically ATII receptors which causes vasoconstriction
 - Primarily acts on **ARTERIAL** vasoconstriction
- ARBs can reduce effect of this
- Dosing/concentration
 - concentrations:
 - High conc. → 2.5 mg/250 mL
 - Standard conc. → 2.5 mg/500 mL
 - Dose: 20-80 ng/kg/min OR 0.02-0.08 mcg/kg/min
- Onset ~ 5 minutes
- Titrate every 5 minutes

CARDIOGENIC SHOCK

Dobutamine (Dobutrex)

- Stimulates β_1 receptors \rightarrow increased inotropic/chronotropic activity
 - Minor β_2 activity
- Indications: Cardiogenic shock
Low CI, Elevated PCWP
- ADRs:
 - Tachycardia
 - Arrhythmias
 - Increased MVO_2 (Myocardial Oxygen Demand)
- Dosing/Concentration
 - 2-20 mcg/kg/min IV
 - MAX: 40 mcg/kg/min
 - Concentration \rightarrow 1000mg/250mL in 5% dextrose IV
OR 250mg/20mL IV

Milrenone (Primacor)

- MOA: Inhibition of phosphodiesterase, reducing the degradation of cAMP leading to enhanced contractility
- Positive inotrope and venodilator
- Indications similar to Dobutamine \rightarrow Theoretically better in pts on Beta-Blockers
- ADRs:
 - Hypotension
 - Arrhythmias
 - Thrombocytopenia
- Dosing/Concentration
 - Dose: 0.375 - 0.75 mcg/kg/min IV
 - MAX: 0.75 mcg/kg/min
 - Concentration: 1mg/mL IV solution

@yourlocalpastudent

CARDIOGENIC SHOCK DEFINITIONS

- SBP $<$ 80 or 90 mmHg
- CI $<$ 2.2 l/min/m²
- PCWP $>$ 18 mmHg

Hemodynamic Goals of Tailored Therapy

- MAP $>$ 60
- CI $>$ 2.2
- PCWP 14-18 mmHg
- CVP 8-12 mmHg
- SVR $<$ 800

CARDIOGENIC SHOCK SUBSETS

SUBSET I

- Lowest mortality subset
- Normal PCWP and CI
(warm and dry)
- Tx: Optimize chronic oral therapy
 - ACEi, BB, Diuretics

SUBSET II

- Elevated PCWP & normal CI
(warm and wet)
- Tx: Reduce preload (PCWP) w/ loop diuretics
 - Nitroglycerin for pulm. edema

SUBSET III

- Normal PCWP & Low CI
(cool and dry)
- CM: si/sx of hypoperfusion
- Tx:
 - Fluids
 - Dobutamine, Milrinone
 - Nitroglycerin can be considered if normotensive

SUBSET IV

- HIGHEST mortality subset
- Elevated PCWP & Low CI
(cold and wet)
- Tx:
 - Vasopressors (Dopamine) if MAP < 50
 - Diuretics
 - Pulmonary vasodilator w/ NTA

@yourlocalpastudent